Novo Plans Phase III Program To Pick Up Obesity Claim For Victoza
This article was originally published in Pharmaceutical Approvals Monthly
Novo Nordisk is moving ahead with plans to develop Victoza (liraglutide) for obesity now that U.S. regulators are comfortable with the GLP-1's risk/benefit profile
You may also be interested in...
New head-to-head study against popular oral Januvia could bolster case for use as a second-line agent in diabetes, company says.
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011